Dr. Oz urges senators to reject Budd hemp amendment
CMS Administrator Dr Mehmet Oz urged senators to reject Senator Ted Budd’s amendment to a short-term government funding bill. The amendment sought to remove a provision delaying a planned federal ban on most intoxicating hemp-derived products, making the dispute significant for both consumer access and the future of the hemp industry.
The underlying restrictions, passed in 2025, are due to take effect in November 2026 and would sharply limit products containing THC, including many delta-8 products. Budd argued that the delay would prolong a public-health risk to children, citing a near tenfold rise in cannabis-related emergency-room visits by minors in North Carolina since 2017; supporters of the delay said it would allow time for a safer regulatory framework.
In short
- Oz opposed removing the delay to the hemp-product ban.
- Budd said the ban should take effect as scheduled.
- The dispute concerns products due to face restrictions in November.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Those opposing Budd's amendment argue that the hemp industry requires reasonable time to develop compliant products and business models under a clear regulatory framework. Rather than imposing an abrupt prohibition that could destabilise legitimate businesses, a measured transition period allows policymakers to craft proportionate regulations that distinguish between genuinely harmful products and safer alternatives. This approach prioritises workable governance over panic-driven bans.
The case against
Those supporting Budd's amendment contend that the documented spike in cannabis-related emergency visits among North Carolina minors represents an urgent public health crisis that cannot wait. Intoxicating hemp products are already readily accessible to children under current regulations, and further delays unnecessarily extend this window of vulnerability. Public health must take priority, and safeguarding young people's wellbeing cannot be subordinated to commercial interests.
Explained simply
Hemp and cannabis come from the same plant, but federal law treats them differently. Hemp products can contain small amounts of THC, the substance that causes a high; some products made from hemp, including delta-8 products, can have intoxicating effects.
A federal law passed in 2025 is due to restrict most intoxicating hemp-derived products from November 2026. Senator Ted Budd of North Carolina has argued that delaying the restrictions could put children at risk, pointing to a rise in cannabis-related emergency visits among minors in his state.
Supporters of a delay say it would give lawmakers time to establish rules for testing and safety. The outcome could affect what products consumers can buy and how hemp businesses operate.